Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

623

Participants

Timeline

Start Date

April 1, 2012

Primary Completion Date

December 1, 2012

Study Completion Date

December 21, 2012

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

fluticasone furoate/vilanterol 100/25mcg

inhalation powder

DRUG

tiotropium bromide 18mcg

inhalation powder

Trial Locations (54)

10117

GSK Investigational Site, Berlin

10717

GSK Investigational Site, Berlin

10787

GSK Investigational Site, Berlin

10789

GSK Investigational Site, Berlin

15562

GSK Investigational Site, Rüdersdorf

19055

GSK Investigational Site, Schwerin

22927

GSK Investigational Site, Großhansdorf

23606

GSK Investigational Site, Newport News

28207

GSK Investigational Site, Charlotte

29303

GSK Investigational Site, Spartanburg

29340

GSK Investigational Site, Gaffney

29379

GSK Investigational Site, Union

29615

GSK Investigational Site, Greenville

29678

GSK Investigational Site, Seneca

39112

GSK Investigational Site, Magdeburg

45231

GSK Investigational Site, Cincinnati

60596

GSK Investigational Site, Frankfurt am Main

63263

GSK Investigational Site, Neu-Isenburg

70000

GSK Investigational Site, Bucharest

83814

GSK Investigational Site, Coeur d'Alene

92663

GSK Investigational Site, Newport Beach

97404

GSK Investigational Site, Medford

300310

GSK Investigational Site, Timișoara

400371

GSK Investigational Site, Cluj-Napoca

700115

GSK Investigational Site, Iași

720284

GSK Investigational Site, Suceava

900002

GSK Investigational Site, Constanța

R2H 2A6

GSK Investigational Site, Winnipeg

B2N 1L2

GSK Investigational Site, Truro

M5V 2T3

GSK Investigational Site, Toronto

H2W 1T8

GSK Investigational Site, Montreal

H4J 1C5

GSK Investigational Site, Montreal

H4N 3C5

GSK Investigational Site, Montreal

G6W 5M6

GSK Investigational Site, Saint Romuald

J6E 2B4

GSK Investigational Site, Saint-Charles-Borromée

J1H 1Z1

GSK Investigational Site, Sherbrooke

278 01

GSK Investigational Site, Kralupy nad Vltavou

767 55

GSK Investigational Site, Kroměříž

415 10

GSK Investigational Site, Teplice

674 01

GSK Investigational Site, Třebíč

564 01

GSK Investigational Site, Žamberk

03050

GSK Investigational Site, Cottbus

01069

GSK Investigational Site, Dresden

04109

GSK Investigational Site, Leipzg

Unknown

GSK Investigational Site, Bialystok

42-200

GSK Investigational Site, Częstochowa

13-200

GSK Investigational Site, Działdowo

31-024

GSK Investigational Site, Krakow

41-940

GSK Investigational Site, Piekary Śląskie

76-200

GSK Investigational Site, Słupsk

33-100

GSK Investigational Site, Tarnów

020125

GSK Investigational Site, Bucharest

030317

GSK Investigational Site, Bucharest

050159

GSK Investigational Site, Bucharest

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01627327 - Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease | Biotech Hunter | Biotech Hunter